Orthopedics Today—September 10, 2018
Michael B. Cross, MD, hip and knee surgeon at HSS, offers his perspective alongside an article about tranexamic acid (TXA) which may reduce transfusion risk after total joint arthroplasty.
Dr. Cross writes that strong evidence supports that perioperative use of TXA decreases postoperative blood loss and reduces the need for postoperative transfusions.
"Although concern remains regarding the risk of prothrombotic adverse events, including deep vein thrombosis, MI, pulmonary embolism and cerebrovascular events with routine use of TXA, the literature has continued to show that use of TXA does not increase the risk of thromboembolic events in TJA," he adds.
Read the full article at Healio.com/Orthopedics.